17.40 USD
▼-1.02-5.54%
盘后 17.35 -0.29%
2026-09-15
市值
$13.88B
市盈率
—
EPS
-1.12
股息率
—
52 周区间
12.07 – 29.23
成交量
5.80M
Beta
-1.24
目标价
29.14
52W 低 12.0752W 高 29.23
价格走势
公司简介
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto...
关联新闻
- These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.